Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 5/20 | 0.35 |
| ▸ | HTR2B | P41595 | 5/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444502 | 0.83 | KCNE1 (0.37) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL13048150 | 0.83 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL30832970 | 0.83 | KCNE1 (0.37) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL2447757 | 0.80 | MEN1 (0.33) | ANPEP | |
| SCHEMBL19200494 | 0.80 | HTR2A (0.44) | KDM1AHTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL17571679 | 0.80 | HTR2A (0.44) | KDM1AHTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL28162183 | 0.80 | HTR2A (0.44) | KDM1AHTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL17571730 | 0.80 | HTR2A (0.44) | KDM1AHTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL2447761 | 0.77 | KCNE1 (0.35) | ANPEP | |
| SCHEMBL5907844 | 0.76 | SIGMAR1 (0.39) | KDM1AHTR2AHTR2CHTR2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435411-B1 | 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8410126-B2 | Pyrimidine inhibitors of PKTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410126-B2 | Pyrimidine inhibitors of PKTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410126-B2 | Pyrimidine inhibitors of PKTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2010136559-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | RB1, MKI67, CCNA1 | KDM1A 1224/4885HTR2A 2158/4885HTR2C 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.